Editas and Vertex Ink Deal for Cas9 License for $50M Upfront
BioSpace
DECEMBER 12, 2023
The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.
BioSpace
DECEMBER 12, 2023
The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.
Pharmaceutical Technology
JANUARY 19, 2023
However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. NiCord’s biologics license application is currently being investigated by the FDA with a review date set by May 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 29, 2022
As of December 16, 2022, there are seven US Food and Drug Administration (FDA) approved gene therapies. In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light.
XTalks
JANUARY 4, 2024
There is a significant focus on developing gene therapies as longer-term solutions for the disease. Pfizer licensed Beqvez from Spark Therapeutics nine years ago. Beqvez is set to rival CSL Behring’s Hemgenix (etranacogene dezaparvovecfor), which was the first gene therapy approved for hemophilia B. Priced at $3.5
XTalks
AUGUST 2, 2023
Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.
Drug Discovery World
FEBRUARY 22, 2024
The FDA has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) injection, for reducing the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease (AD).
Let's personalize your content